Beyond Single‐Target Therapy: Dual‐Acting Cannabinoid Type‐2 Receptor Modulation in Neurological Disorders
ChemMedChem · 2026-10-28 · 21 (20)
DOI: 10.1002/cmdc.70521 ↗At a glance
Übersichtsarbeit in ChemMedChem, published online on 2026-10-13. Written by Sandeep Bindra and 5 co-authors. Institution: Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India. Major MEDLINE topics: Receptor, Cannabinoid, CB2, Nervous System Diseases, Cholinesterase Inhibitors, Neuroprotective Agents. 60 references.
Abstract (original language)
Neurological disorders such as Alzheimer's disease, Parkinson's disease, and neuroinflammatory conditions involve complex, interconnected mechanisms, including neuroinflammation, oxidative stress, cholinergic dysfunction, and synaptic impairment. The cannabinoid type‐2 receptor (CB2R), primarily expressed in immune and glial cells, has emerged as a promising therapeutic target due to its role in modulating neuroinflammation and providing neuroprotection without the psychoactive effects associated with CB1R activation. Recent research highlights the potential of dual‐acting CB2R ligands that also modulate CB1R, acetylcholinesterase (AChE), and butyrylcholinesterase (BChE), offering a multitarget approach to neurological disorders. Although CB1R expression was identified in 1993, significant progress in designing receptor modulators began in the 2000s, with recent focus expanding to autoimmune, metabolic, and cancer‐related applications. This review summarizes advances in the design, synthesis, and structure–activity relationships of CB2R‐targeting ligands, emphasizing dual‐ or multitarget agents with cholinesterase inhibitory activity. Key chemical scaffolds include synthetic cannabinoids, heterocyclic compounds, and hybrid molecules integrating cholinesterase pharmacophores. Molecular docking and in silico studies are discussed to elucidate ligand–receptor interactions, binding modes, and determinants of selectivity. Overall, CB2R‐centric dual‐acting ligands represent a promising strategy for addressing multifactorial neurological disorders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
- Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India.
- Department of Chemistry, Sri Venkateswara College, University of Delhi, New Delhi, India.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Aljouf, Saudi Arabia.
- School of Pharmacy & DST-FIST, Sharda University, Greater Noida, Uttar Pradesh, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
ORCID profiles: T M Rangarajan, Della Grace Thomas Parambi, Sandeep Kumar, Jasha Momo H Anal, Bijo Mathew
Cite
APA
Bindra, S., Rangarajan, T. M., Parambi, D. G. T., Kumar, S., Anal, J. M. H., & Mathew, B. (2026). Beyond Single‐Target Therapy: Dual‐Acting Cannabinoid Type‐2 Receptor Modulation in Neurological Disorders. ChemMedChem, 21(20). https://doi.org/10.1002/cmdc.70521
Vancouver
Bindra S, Rangarajan TM, Parambi DGT, Kumar S, Anal JMH, Mathew B. Beyond Single‐Target Therapy: Dual‐Acting Cannabinoid Type‐2 Receptor Modulation in Neurological Disorders. ChemMedChem. 2026;21(20). doi:10.1002/cmdc.70521
BibTeX
@article{Bindra2026,
author = {Bindra, Sandeep and Rangarajan, T M and Parambi, Della Grace Thomas and Kumar, Sandeep and Anal, Jasha Momo H and Mathew, Bijo},
title = {Beyond Single‐Target Therapy: Dual‐Acting Cannabinoid Type‐2 Receptor Modulation in Neurological Disorders},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {20},
doi = {10.1002/cmdc.70521}
}
EUVIMED